Catalent Inc., a New Jersey-based contract drug manufacturer, said Monday it will acquire Maryland’s Paragon Bioservices Inc. for $1.2 billion. Catalent (NYSE: CTLTC) will fund the acquisition using the proceeds of a $650 million incremental term loan from JPMorgan Chase Bank, as well as the issuance of $650 million of new convertible preferred stock to Leonard Green & Partners L.P. Peter Zippelius, a partner at LGP, will join Catalent’s board of directors as part of the new investment. The all-cash…
from https://www.bizjournals.com/baltimore/news/2019/04/15/new-jersey-drug-maker-to-buy-marylands-paragon.html?ana=RSS&s=article_search
via http://baltimorecheckbook.tumblr.com/post/184203244197
No comments:
Post a Comment